for 弥漫性肝癌 ( diffuse hepatocellular carcinoma).
TACE: transarterial chemoembolization or Transcatheter arterial chemoembolization
The result of liver transplant is not good at all:
EVOLUTION OF TRANSPLANTATION FOR HCC
Liver transplantation for treatment of hepatocellular carcinoma (HCC) is attractive because resection of the malignant tumor can be achieved while also replacing the cirrhotic liver that remains at risk for the development of new lesions. However, early experience with transplantation for patients with unresectable local HCC was disappointing. Unacceptable 90-day mortality rates, tumor recurrence in up to 80 percent of patients, and long-term survival rates that were well below that of patients transplanted for nonmalignant disease all reflected the advanced nature of the disease [2,3].